PLSE vs MMED
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PLSE · Pulse Biosciences$45.55 ▲ 2.57%
MMED · MiniMed Group$16.01 ▼ 1.54%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PLSE +151.1%
- MMED -13.4%
Head to head
| Metric | PLSE | MMED |
|---|---|---|
| Price | $45.55 | $16.01 |
| Change today | ▲ 2.57% | ▼ 1.54% |
| Market cap | $3.35B | $4.50B |
| Return, 3 months | -7.3% | -19.7% |
| Return, year to date | +231.8% | – |
| Return, 1 year | +250.1% | – |
| P/E (TTM) | – | – |
| P/B | 18.2 | 1.2 |
| P/E percentile vs own 5y | 4th | 34th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +359.3% | +16.6% |
| Net profit growth (YoY) | -18.9% | +100.0% |
| Gross margin | 26.8% | 53.9% |
| Operating margin | -5,821.1% | -5.0% |
| Net margin | -5,603.9% | -9.7% |
| Return on equity | -60.6% | -8.7% |
| Analyst target vs. price | +46.4% | +65.0% |
| Analyst buy share | 100% | 85% |
| RSI (14) | 41 | 37 |
| 30-day volatility | 76.9% | 64.9% |
| Max drawdown, 1 year | -29.5% | -41.6% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MMED is the largest of the group by market value.
- PLSE is growing revenue fastest.
- MMED keeps the most profit per dollar of sales.
- MMED has been the calmest stock over the last 30 days.